Compounds and methods

A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• X is hydrogen or one or more of C1-6alkyl, CONRR′, trifluoromethyl, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo where R and R′ are independently hydrogen or C1-6alkyl;
• R1 is hydrogen or C1-6alkyl;
• R2 is hydrogen or C1-6alkyl;
• the dotted line, . . . , indicates a single bond or a double bond;
• R3 is hydrogen or C1-6alkyl;
• A is [C(R″)2]m CR″R4R5 or [C(R″)2]nCR″=C R4R5 where each R″ is independently hydrogen or C1-6alkyl;
• m is 0-3;
• n is 1-2
• R4 is phenyl, biphenyl, naphthyl, 1-benzotriazinyl, or 2-benzotriazinyl, optionally substituted with one or more of C1-6alkyl, cyano, trifluoromethyl, NR6R7, nitro, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo, where R6 and R7 are independently hydrogen or C1-6alkyl;
• R5 is R′ when m is 0;
• alternatively, R5 is R″, phenyl or naphthyl when m is 1-3 or n is 1-2, wherein phenyl or naphthyl are optionally substituted with one or more of C1-6alkyl, cyano, trifluoromethyl, NR6R7, nitro, hydroxy, C1-6alkoxy, benzyloxy, C1-6alkylthio, or halo.